Markus Maeurer - Biography#

Markus J Maeurer received 1989 his Medical degree at the Johannes Gutenberg University of Mainz, Germany; Research Fellow at the Department of Surgical Oncology, University of Pittsburgh, USA, Assist. Prof of Surgical Oncology and Immunotherapy at UPMC, Pittsburgh, PA, USA. 1999 full Professor of Microbiology and Infectious Diseases at the University of Mainz and and Head of the diagnostic Laboratory at the Department of Medical Microbiology¨2005 Professor of Infectious Diseases, particularly Clinical Immunology, at the Karolinska Institute, at the MTC (Microbiology, Tumor Biology Center). He served then as head of the division Therapeutic Immunology at Karolinska Institute and Senior Physician of the Center for allogeneic stem cell transplantation, CAST, Karolinska Hospital 2012-2017.

Dr. Maeurer is head of immunotherapy / ImmunoSurgery at the Champalimaud Foundation, Lisbon, he is director of the Cell Center at the Champalimaud Foundation and Full Professor at the I Medical Clinic of the University of Mainz, Germany, published more than 310 scientific articles, 28 among them in the LANCET series, he created 9 patents, he serves as a reviewer for several international grant agencies and governments (Italy, Norway and the UK) and several high impact journals.

Advisor for the Bill and Melinda Gates Foundation, for the UK Parliament and the Italian Government, Fellow of the Royal Chamber of Physicians, London; initiated with Sir Alimuddin Zumla (UCL, UK) the consortium against cancer and infectious diseases with a particular focus on COVID-19 (https://www.fchampalimaud.org/covid19). Dr. Maeurer is heading several international partnership projects with academia and industries with a focus on i) examining the tumor microbiome for T-cell targets and ii) genetic T-cell engineering. He is responsible for governing the newly established GMP facility (for GMP and non-GMOs) at the Champalimaud Foundation. The Foundation acquired more recently exclusive rights and IP to use CRISPR for genetic engineering of immune cells in order to design smart cell therapies for patients with solid cancer and Dr. Maeurer is moving cell therapy, along with international clinical partner institutions along with an internationally highly recognized advisory team, into a robust phase I clinical trials. Prof Maeurer initiated with Prof Christoph Huber, the founder of BioNtech, a strong partnership between CIMT and the Champalimaud Foundation and organized in 2024 the summer school for immunotherapy (www.cimt.eu/summer-school )and the European cell therapy (www.cimt.eu/cancer-cell-therapy-summit) with world renowned opinion leaders in cell therapy.